Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
SYRE
$91.40
+7.88%
SYRE
· Spyre Therapeutics, Inc.
$91.40
+6.68 (+7.88%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$7.47B
Shares
88.17M
Volume · Oct 20
1.5M
Avg daily vol (3M)
1.21M
All webcasts
Earnings call · FY2019 Q4
Spyre Therapeutics, Inc. (SYRE) Q4 2019 Earnings Call
Net income
-$21.50M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Feb 24, 2020 · complete as-filed document
SEC periodic report
10-K report
Filed Feb 24, 2020 · complete as-filed document